6ER-011 Drug utilisation study of bevacizumab in a teaching referral paediatric hospital

BACKGROUND: Bevacizumab is a humanised monoclonal antibody against vascular endothelial growth factor authorised for adult cancer treatments. There are several case series and clinical trials on the use of bevacizumab in paediatric tumours at dose range of 5 to 15 mg/kg every 2 to 4 weeks. PURPOSE:...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Celma, M Sánchez, Busquets, F Bossacoma, Genestar, JL Vinent, Suárez, J Arrojo, Flaqué, M Villaronga, Escoda, A Comes, López, V Santa-María, Alcón, P Montoliu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Section 6: Education and research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535719/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.504
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller